Skip to main content

OPTIMIZANDO ESTRATEGIAS DE SECUENCIACION MASIVA PARA LA IDENTIFICACION Y TRASLACION A LA CLINICA DE NUEVOS GENES DE SUSCEPTIBILIDAD IMPLICADOS EN CANCER DE MAMA FAMILIAR

PI19/00640

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION CENTRO NAL DE INV. ONCOLOGICAS
Execution centre FUNDACION CENTRO NAL DE INV. ONCOLOGICAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Figlioli, Gisella
  • Kvist, Anders
  • Tham, Emma
  • Soukupova, Jana
  • Kleiblova, Petra
  • Muranen, Taru A
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
Predisposició al càncer de mama; Factors de risc de càncer de mama; Espectre de mutació, Predisposición al cáncer de mama; Factores de riesgo de cáncer de mama; Espectro de mutación, Breast cancer predisposition; Breast cancer risk factors; Mutation spectrum, Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases., This research was partially funded by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo, a fellowship from Fondazione Umberto Veronesi to G. Figlioli and by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. E. Tham is supported by Region Stockholm (ALF). The Czech study was supported by a grant of the Ministry of Health of the Czech Republic NV16-29959A. CNIO study was partially supported by projects PI16/00440 and PI19/00640, supported by the Instituto de Salud Carlos III, cofunded by European Regional Development Fund (ERDF), the Spanish Network on Rare Diseases (CIBERER) and BRIDGES project H2020. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654). HEBCS was funded by Helsinki University Hospital Research Fund, Sigrid Juselius Foundation, The cancer Society of Finland. A.Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII) through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). This work was supported by the Australian National Health and Medical Research Council (APP1029974 and APP1074383) and by a Victorian Life Sciences Computation Initiative grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government. T.N-D is a Career Development Fellow of the National Breast Cancer Foundation (Australia, ECF-17-001). M.C.S. is a National Health and Medical Research Council (Australia) Senior Research Fellow. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 to E. Olah. Lithuanian study was supported by The Research Council of Lithuania grant SEN18/2015 and P-MIP-20-25 to R. Janavicius. The ICO was supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI16/00563, PI19/00553 and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS) Project MedPerCan, 2017SGR1282 and 2017SGR496]; and CERCA program.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects

  • Baquero, Juan Miguel|||0000-0002-6488-7742
  • Benítez-Buelga, Carlos
  • Rajagopal, Varshni
  • Zhenjun, Zhao
  • Torres, Raul|||0000-0001-9606-0398
  • Müller, Sarah
  • Hanna, Bishoy M. F.|||0000-0001-7027-6553
  • Loseva, Olga
  • Wallner, Olov|||0000-0002-6481-237X
  • Michel, Maurice|||0000-0003-3261-2493
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Gad, Helge|||0000-0001-6530-1443
  • Visnes, Torkild|||0000-0003-1047-988X
  • Helleday, Thomas|||0000-0002-7384-092X
  • Benitez, Javier|||0000-0002-0923-7202
  • Osorio, Ana|||0000-0001-8124-3984
The most common oxidative DNA lesion is 8-oxoguanine which is mainly recognized and excised by the 8-oxoG DNA glycosylase 1 (OGG1), initiating the base excision repair (BER) pathway. Telomeres are particularly sensitive to oxidative stress (OS) which disrupts telomere homeostasis triggering genome instability. In the present study, we have investigated the effects of inactivating BER in OS conditions, by using a specific inhibitor of OGG1 (TH5487). We have found that in OS conditions, TH5487 blocks BER initiation at telomeres causing an accumulation of oxidized bases, that is correlated with telomere losses, micronuclei formation and mild proliferation defects. Moreover, the antimetabolite methotrexate synergizes with TH5487 through induction of intracellular reactive oxygen species (ROS) formation, which potentiates TH5487-mediated telomere and genome instability. Our findings demonstrate that OGG1 is required to protect telomeres from OS and present OGG1 inhibitors as a tool to induce oxidative DNA damage at telomeres, with the potential for developing new combination therapies for cancer treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

p53 and ovarian carcinoma survival, an Ovarian Tumor Tissue Analysis consortium study

  • Köbel, Martin|||0000-0002-6615-2037
  • Kang, Eun-Yyoung
  • Weir, Ashley|||0000-0002-3072-2616
  • Rambau, Peter F.
  • Lee, Cheng-Han
  • Nelson, Gregg S.
  • Ghatage, Prafull
  • Meagher, Nicola S.
  • Riggan, Mrjorie J.
  • Alsop, Jennifer
  • Anglesio, Michael|||0000-0003-1639-5003
  • Beckmann, Matthias W.
  • Bisinotto, Christiani
  • Boisen, Michelle
  • Boros, Jessica
  • Brand, Alison H.
  • Brooks-Wilson, Angela
  • Carney, Michael E.
  • Coulson, Penny
  • Courtney-Brooks, Madeleine
  • Cushing-Haugen, Kara L.
  • Cybulski, Cezary|||0000-0002-2819-3057
  • Deen, S.
  • El-Bahrawy, M.A.
  • Elishaev, E.
  • Erber, R.|||0000-0003-0315-1229
  • Fereday, Sian|||0000-0002-8559-8579
  • Fischer, A.
  • Gayther, S.A.
  • Barquin-Garcia, A.
  • Gentry-Maharaj, A.
  • Gilks, C.B.|||0000-0001-7889-8250
  • Gronwald, H.
  • Grube, M.
  • Harnett, P.R.
  • Harris, H.R.
  • Hartkopf, A.D.
  • Hartmann, Andreas
  • Hein, A.
  • Hendley, J.
  • Hernandez, B.Y.
  • Huang, Y.
  • Jakubowska, A.
  • Jimenez-Linan, M.
  • Jones, M.E.
  • Kennedy, C.J.
  • Kluz, T.
  • Koziak, J.M.
  • Lesnock, J.
  • Lester, J.
  • Lubiński, J.
  • Longacre, T.A.
  • Lycke, M.
  • Mateoiu, C.
  • McCauley, Bryan M.
  • McGuire, V.
  • Ney, B.
  • Olawaiye, A.
  • Orsulic, S.
  • Osorio, Ana|||0000-0001-8124-3984
  • Paz-Ares, L.
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Rothstein, J.H.
  • Ruebner, M.
  • Schoemaker, M.J.
  • Shah, M.
  • Sharma, R.
  • Sherman, M.E.
  • Shvetsov, Y.B.|||0000-0001-5131-9618
  • Singh, N.
  • Steed, H.
  • Storr, S.J.
  • Talhouk, Aline
  • Traficante, Nadia|||0000-0001-7459-8576
  • Wang, Chen
  • Whittemore, Alice S.
  • Widschwendter, Martin
  • Wilkens, Lynne R.
  • Winham, Stacey J.|||0000-0002-8492-9102
  • Benitez, Javier|||0000-0002-0923-7202
  • Berchuck, Andrew
  • Bowtell, David D.
  • Candido dos Reis, Francisco J.
  • Campbell, Ian|||0000-0002-7773-4155
  • Cook, Linda S.
  • deFazio, Anna|||0000-0003-0057-4744
  • Doherty, Jennifer A.
  • Fasching, Peter A.
  • Fortner, Renée T.
  • García, María J.
  • Goodman, Marc T.
  • Goode, Ellen L.|||0000-0002-9094-8326
  • Gronwald, Jacek
  • Huntsman, David G.|||0000-0003-4934-3322
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Kelemen, Linda E.
  • Kommoss, Stefan
  • Le, Nhu D.
  • Martin, Stewart G.
  • Menon, Usha|||0000-0003-3708-1732
  • Modugno, Francesmary
  • Pharoah, Paul D.P.|||0000-0001-8494-732X
  • Schildkraut, Joellen M.
  • Sieh, Weiva
  • Staebler, Annette
  • Sundfeldt, Karin
  • Swerdlow, Anthony J.
  • Ramus, Susan J.|||0000-0003-0005-7798
  • Brenton, James D.|||0000-0002-5738-6683
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Figlioli, Gisella
  • Kvist, Anders
  • Tham, Emma
  • Soukupova, Jana
  • Kleiblova, Petra
  • Muranen, Taru A
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
Predisposició al càncer de mama; Factors de risc de càncer de mama; Espectre de mutació, Predisposición al cáncer de mama; Factores de riesgo de cáncer de mama; Espectro de mutación, Breast cancer predisposition; Breast cancer risk factors; Mutation spectrum, Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases., This research was partially funded by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo, a fellowship from Fondazione Umberto Veronesi to G. Figlioli and by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. E. Tham is supported by Region Stockholm (ALF). The Czech study was supported by a grant of the Ministry of Health of the Czech Republic NV16-29959A. CNIO study was partially supported by projects PI16/00440 and PI19/00640, supported by the Instituto de Salud Carlos III, cofunded by European Regional Development Fund (ERDF), the Spanish Network on Rare Diseases (CIBERER) and BRIDGES project H2020. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654). HEBCS was funded by Helsinki University Hospital Research Fund, Sigrid Juselius Foundation, The cancer Society of Finland. A.Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII) through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). This work was supported by the Australian National Health and Medical Research Council (APP1029974 and APP1074383) and by a Victorian Life Sciences Computation Initiative grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government. T.N-D is a Career Development Fellow of the National Breast Cancer Foundation (Australia, ECF-17-001). M.C.S. is a National Health and Medical Research Council (Australia) Senior Research Fellow. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 to E. Olah. Lithuanian study was supported by The Research Council of Lithuania grant SEN18/2015 and P-MIP-20-25 to R. Janavicius. The ICO was supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI16/00563, PI19/00553 and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS) Project MedPerCan, 2017SGR1282 and 2017SGR496]; and CERCA program.